Can taking SGLT2 inhibitors help reduce the chance of atrial arrhythmia coming back after catheter ablation?
After catheter ablation for atrial fibrillation (AF), some people still have atrial arrhythmia come back. SGLT2 inhibitors are diabetes drugs that also help the heart. Research suggests these drugs may lower the risk of AF returning after ablation, particularly in patients who also have heart failure.
What the research says
A 2023 study combined a retrospective cohort (168 patients with AF and heart failure) and a meta-analysis of 13 studies (7,954 patients). It found that SGLT2 inhibitor use was linked to a significantly lower rate of atrial arrhythmia recurrence after ablation (13.25% vs. 25.88% in the cohort). The meta-analysis showed a 41% lower risk of recurrence (RR 0.59, 95% CI 0.51–0.69) 3. The cohort also found that SGLT2 inhibitors were an independent predictor of lower recurrence (HR 0.45) 3. These results are promising but come mostly from observational studies, not large randomized trials. Other sources confirm the heart benefits of SGLT2 inhibitors in general, but do not directly address ablation outcomes 45.
What to ask your doctor
- Based on my heart function and diabetes status, could an SGLT2 inhibitor help prevent AF from coming back after my ablation?
- What are the potential side effects of SGLT2 inhibitors, and how do they compare with other options?
- If I already take a different diabetes medication, can I switch to or add an SGLT2 inhibitor?
- How long would I need to take an SGLT2 inhibitor to see a benefit for arrhythmia prevention?
This question is drawn from common patient questions about Cardiology and answered using cited medical research. We do not provide individualized advice.